Drug Target Review

OCTOBER 3, 2024

Overcoming traditional antibody generation limitations with recombinant technologies Antibodies remain essential tools in this ever-changing field for preclinical bioanalysis and drug monitoring through ligand-binding assays (LBAs). FDA no longer needs to require animal tests before human drug trials [Internet]. www.science.org.

Molecular Biology 52

Molecular Biology Pharmacokinetics Laboratories Animal Testing 52

Drug Target Review

SEPTEMBER 19, 2023

Pharmaceutical companies adapted the usage of organoids derived from specific patient derived tumours in cancer drug screening process for testing drug toxicities and efficacy. Human In Silico Drug Trials Demonstrate Higher Accuracy than Animal Models in Predicting Clinical Pro-Arrhythmic Cardiotoxicity. Nature Cancer.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Alta Sciences

JULY 31, 2024

Why Diversity in Clinical Trials Matters A wide variety of factors, from age or biological sex to environmental conditions and lifestyle choices (e.g., substance abuse, sexual activity), can influence the risk and likelihood of developing a disease or other long-term health issues—as well as the way an individual responds to treatment.

Clinical Trials 52

Clinical Trials Trials Clinical Pharmacology Pharmacokinetics 52